This year’s American Association for Cancer Research Annual Meeting featured several potentially practice-changing studies, including many that evaluated novel immunotherapy regimens and assessed biomarkers that may predict treatment response.
HemOnc Today presents 10 updates from the meeting that may affect your practice. The addition of the anti-PD-1 therapy pembrolizumab (Keytruda, Merck) to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who did not harbor EGFR or ALK alterations… Read more . . .